Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Debt to Equity (2016 - 2025)

Avalo Therapeutics filings provide 11 years of Debt to Equity readings, the most recent being $0.0 for Q2 2025.

  • On a quarterly basis, Debt to Equity changed N/A to $0.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $0.0, a N/A change, with the full-year FY2024 number at $0.0, changed N/A from a year prior.
  • Debt to Equity hit $0.0 in Q2 2025 for Avalo Therapeutics, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1.42 in Q4 2021 to a low of -$8.14 in Q3 2022.
  • Median Debt to Equity over the past 5 years was -$0.62 (2022), compared with a mean of -$1.59.
  • The widest YoY moves for Debt to Equity: up 186.86% in 2022, down 186.86% in 2022.
  • Avalo Therapeutics' Debt to Equity stood at $1.42 in 2021, then crashed by 186.86% to -$1.24 in 2022, then crashed by 35.22% to -$1.67 in 2023, then soared by 100.16% to $0.0 in 2024, then soared by 30.75% to $0.0 in 2025.
  • The last three reported values for Debt to Equity were $0.0 (Q2 2025), $0.0 (Q1 2025), and $0.0 (Q4 2024) per Business Quant data.